- Home
- UHG vs AARD Comparison
UHG vs AARD Comparison
Compare UHG & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- AARD
- Stock Information
- Founded
- UHG 2004
- AARD 2017
- Country
- UHG United States
- AARD United States
- Employees
- UHG N/A
- AARD N/A
- Industry
- UHG Homebuilding
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- UHG Consumer Discretionary
- AARD Health Care
- Exchange
- UHG Nasdaq
- AARD Nasdaq
- Market Cap
- UHG 152.4M
- AARD 154.9M
- IPO Year
- UHG N/A
- AARD 2025
- Fundamental
- Price
- UHG $3.31
- AARD $11.13
- Analyst Decision
- UHG
- AARD Strong Buy
- Analyst Count
- UHG 0
- AARD 4
- Target Price
- UHG N/A
- AARD $31.25
- AVG Volume (30 Days)
- UHG 338.1K
- AARD 31.4K
- Earning Date
- UHG 08-07-2025
- AARD 08-14-2025
- Dividend Yield
- UHG N/A
- AARD N/A
- EPS Growth
- UHG N/A
- AARD N/A
- EPS
- UHG 0.76
- AARD N/A
- Revenue
- UHG $449,877,017.00
- AARD N/A
- Revenue This Year
- UHG N/A
- AARD N/A
- Revenue Next Year
- UHG N/A
- AARD N/A
- P/E Ratio
- UHG $4.35
- AARD N/A
- Revenue Growth
- UHG 5.24
- AARD N/A
- 52 Week Low
- UHG $1.60
- AARD $4.88
- 52 Week High
- UHG $6.93
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- UHG 56.38
- AARD N/A
- Support Level
- UHG $3.10
- AARD N/A
- Resistance Level
- UHG $3.70
- AARD N/A
- Average True Range (ATR)
- UHG 0.41
- AARD 0.00
- MACD
- UHG -0.04
- AARD 0.00
- Stochastic Oscillator
- UHG 19.54
- AARD 0.00
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.